Alpha Teknova, Inc.
Alpha Teknova, Inc.
Your view on TKNO
Overview
What the company does, where it operates, and who runs it.
About Alpha Teknova, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Stephen Gunstream
- Headquarters
- 2290 Bert Drive, Hollister, CA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Stephen Gunstream
- Headquarters
- 2290 Bert Drive, Hollister, CA, US
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics.
The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Alpha Teknova, Inc., and the rating behind it. TKNO last traded at $6.71; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Alpha Teknova, Inc.. Starting points for Alpha Teknova, Inc.: EPS -$0.31, beta 0.73 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Alpha Teknova, Inc.. Alpha Teknova, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Alpha Teknova, Inc.. Trailing twelve-month EPS for Alpha Teknova, Inc. stands at -$0.31. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Alpha Teknova, Inc.. Alpha Teknova, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Alpha Teknova, Inc. valued side by side against its closest peers. Alpha Teknova, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Alpha Teknova, Inc., and how their positions are changing. At a $359.7M market value, institutional positions materially move Alpha Teknova, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Alpha Teknova, Inc. executives and directors. Shares of Alpha Teknova, Inc. have traded between $3.94 and $10.37 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Alpha Teknova, Inc.. Alpha Teknova, Inc. is a $359.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Alpha Teknova, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Alpha Teknova, Inc.. Coverage tracks Alpha Teknova, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.